LIFE MEDICAL TECHNOLOGIES INC /UT/
10QSB, 2000-01-07
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Previous: LIFE MEDICAL TECHNOLOGIES INC /UT/, 10QSB, 2000-01-07
Next: LIFE MEDICAL TECHNOLOGIES INC /UT/, 10KSB, 2000-01-07




                                	FORM 10-QSB

                        	SECURITIES AND EXCHANGE COMMISSION
                            	Washington D.C.  20549

                    	Quarterly Report Under Section 13 or 15 (d)
                      	Of the Securities Exchange Act of 1934


                  	For Quarter Ended        September 30, 1999

                   	Commission File Number    33-26787-0


	                        LIFE MEDICAL TECHNOLOGIES, INC.
             	(Exact name of registrant as specified in its charter)


       DELAWARE                                 87-0403828
	(State or other jurisdiction of               (IRS Employer
	incorporation or organization)               Identification No.)


                      	6975 SOUTH UNION PARK DRIVE #600
                 	       SALT LAKE CITY, UTAH  84047
                    	(Address of principal executive offices)


Registrant's telephone number
including area code                          	          (801) 256-9600



	Former Address, if changed since last report

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15 (d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or such shorter period that the
registrant was required to file such reports)

      	Yes       No  X

and (2) has been subject to such filing requirements for the past 90 days.


	Yes X    No


                                25,424,317
                      	(Number of shares of common
                       	stock the registrant had
                      	outstanding as of November 30, 1999)


PART 1

ITEM 1 - FINANCIAL STATEMENTS

	The condensed financial statements included herein have been prepared by
the Company, without audit, pursuant to the rules and regulations of the
Securities and Exchange Commission.  Certain information and footnote
disclosures normally included in financial statements prepared in accordance
with generally accepted accounting principles have been condensed or omitted
pursuant to such rules and regulations, although the Company believes that
the disclosures are adequate to make the information presented not misleading.


	In the opinion of the Company, all adjustments, consisting of only normal
recurring adjustments, necessary to present fairly the financial position of
the Company as of September 30, 1999 and the results of its operations and
changes in its financial position from June 30, 1999 through September 30,
1999 have been made.  The results of its operations for such interim period
is not necessarily indicative of the results to be expected for the entire
year.

                     Life Medical Technologies, Inc.
                             Balance Sheet


                                 	ASSETS
                                               		September 30,			December 31,
                                                   		1999      			1998

Organization costs (Note 1)	                         $	-        		$	122

TOTAL ASSETS	                                        $	-        		$	122


	STOCKHOLDERS' EQUITY

Preferred stock 5,000,000 shares authorized
     at $.001 par value; 0 shares outstanding         		-       			-
Common stock, 150,000,000 shares authorized
     at $.001 par value; 25,424,317 and 144,317 shares
     issued and outstanding, respectively            		25,424	  		144
Capital in Excess of Par Value		                     1,838,110	 		1,838,110
Retained Deficit		                                   (1,838,254	) (1,838,132)

Total Stockholders' Equity                             		25,280	  		122

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	              $	-    		$	122



                        Life Medical Technologies, Inc.
                             Statements of Operations


   					            For the Three  For the Three  For the Nine  For the Nine
				               	Months Ended 		Months Ended 	Months Ended   Months Ended
		     		         	September 30, 		September 30,	September 30,  September 30,
             					    1999        	    1998           1999          1998

REVENUE

      Sales			          $	-          	$	3,259	       $	-   	$	12,414

EXPENSES

      Officer Compensation	25,000 				               25,000
      Legal Services				      280 			                  	280
      Cost of sales (Note 1)				-   		1,629		-   		6,207
      Amortization (Note 1)				-   		92		122 		275
      Selling, general and administrative			-   		14,877		-   		17,183
      Interest				-   		1,247		-   		5,850

      Total Expenses				25,280 		17,845		25,402 		29,515

OTHER INCOME/EXPENSES

      Interest 				-   		129 		-   		352

NET INCOME (LOSS) - Before Taxes			(25,280)		(14,457)		(25,402)		(16,749)

      Taxes				-   		-   		-   		-

INCOME (LOSS)			$	(25,280)	$	(14,457)	$	(25,402)	$	(16,749)

Loss Per Common Share			$	(0.00)	$	(.026)	$	(0.00)	$	(.31)

Average Outstanding Shares				25,424,317		54,797		25,424,317		54,797

                 Life Medical Technologies, Inc.
                     Statements of Cash Flows

				                                       For the Nine       For the Nine
                            				           Months Ended       Months Ended
					                                      September 30, 		   September 30,
					                                         1999        	       1998

CASH FLOW FROM
   OPERATING ACTIVITIES
	Net Income (Loss)		                         	$		(25,402)	$		(16,749	)
	Amortization				                                   	122 	    		275
	Increase (decrease)
		In inventory & accounts receivable	             				-   		 	7,288
		In accounts payable			                            		-   			(18,300	)
	Expenses paid by stock issuance	                 				25,280			6,765

Net Increase in Cash Flows From
   Operating Activities					                           -     			-

CASH FLOWS FROM
    INVESTING ACTIVITIES				                           	-   	 		-

CASH FLOWS FROM
   FINANCING ACTIVITIES			                             		-   			-

INCREASE (DECREASE) IN CASH
   AND CASH EQUIVALENTS                            					-   	 		(6,355	)

CASH AND CASH EQUIVALENTS
   AT BEGINNING OF PERIOD			                            		-   			6,355

CASH AND CASH EQUIVALENTS
   AT END OF PERIOD                                  				$	-   		$	-

CASH PAID DURING THE PERIOD FOR:
	Interest                                            				$	-   		$	-
	Income Taxes				                                        $	-   		$	-


                     Life Medical Technologies, Inc.
                    Notes to the Financial Statements
                           September 30, 1999

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES

	Background and History Life Medical Technologies was organized on December
26, 1991  in the State of Delaware.  It was in the business of bringing
simple, cost effective, new medical product technology to the health care
market place.  By 1998, sales and marketing had declined to non operations
status and the remaining assets were spunoff to its wholly owned subsidiary
and sold to two former employees of the Company.

	Cash and Cash Equivalents The Company considers all highly liquid
investments with maturities of three months or less to be cash equivalents.

	Organization Costs Organization costs are being amortized over a sixty month
period on a straight line basis.  Amortization for 1999, 1998 and 1997 was
$122, $366 and $387, respectively.

NOTE 2 - INCOME TAXES

	The Company adopted Statement of Financial Standards No. 109 "Accounting
for Income Taxes" in the fiscal year ended December 31, 1998 and was applied
retroactively.

	Statement of Financial Accounting Standards No. 109 "Accounting for Income
Taxes" requires an asset and liability approach for financial accounting and
reporting for income tax purposes.  This statement recognizes (a) the amount
of taxes payable or refundable for the current year and (b) deferred tax
liabilities and assets for future tax consequences of events that have been
recognized in the financial statements or tax returns.

	Deferred income taxes result from temporary differences in the recognition
of accounting transactions for tax and financial purposes.  There were no
temporary differences at December 31, 1998 and earlier years; accordingly, no
deferred tax liabilities have been recognized for all years.

	The Company has cumulative net operating loss carryforwards of over
$1,000,000 at December 31, 1998.  No effect has been shown in the financial
statements for the net operating loss carryforwards as the likelihood of
future tax benefit from such net operating loss carryforwards is highly
improbable.  Accordingly, the potential tax benefits of the net operating
loss carryforwards, estimated based upon current tax rates at December 31,
1998 have been offset by valuation reserves of the same amount.



                         Life Medical Technologies, Inc.
                         	Notes to Financial Statements
                             	September 30, 1998

NOTE 3 - USE OF ESTIMATES IN THE PREPARATION OF FINANCIAL STATEMENTS

	The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect reported amounts of assets and liabilities,
disclosure of contingent assets and liabilities at the date of the financial
statements and revenues and expenses during the reporting period.  In these
financial statements, assets, liabilities and earnings involve extensive
reliance on management's estimates.  Actual results could differ from those

NOTE 4 - COMMON STOCK TRANSACTIONS

	In 1998, the shareholders approved a change in the capital structure of
the Company to increase the authorized stock to 5,000,000 shares preferred
$.001 par value and 150,000,000 shares authorized $.001 par value.  The
change was made effective with the State of Delaware on June 7, 1999.

NOTE 5 - REVERSE STOCK SPLIT/BOARD ACTIONS

	In 1998, board of directors authorized a 1 for 1000 reverse stock split
upon approval by the stockholders.  The reverse split was affected in 1999.
The financial statements for all periods have been restated to reflect the
reverse stock split.

	In 1998, the board of directors also authorized several issuances of stock
for services rendered to the Company.  A total of 25,280,000 post reverse
split shares were issued upon the reverse stock split.  Of the total shares,
25,000,000 were issued for officer compensation and 280,000 for legal
services rendered.  The shares were issued in July 1999.


ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
         RESULTS OF OPERATIONS.

	Liquidity and Capital Resources.  The Registrant had $0 as operating capital
at September 30, 1999.  The Registrant intends to raise additional funds as
needed through private placements with accredited and sophisticated investors.

	Results of Operation.  Due to the lack of operations during the quarter
ended September 30, 1999, the registrant had net loss of $(25,280), compared
to net loss of $(14,457) for the same period last year. The registrant had
net loss of $(25,402) for the nine months ended September 30, 1999, compared
to $(16,749) for the same period last year.

	Plan of Operations.  The Company is currently in the process of looking for
business opportunities to acquire or merge with.  There is no guarantee that
management will be successful in finding such an opportunity.  The Company is
also in the process of bringing all of its periodic reports current for
filing with the Securities and Exchange Commission. During this process, the
Company intends to raise operational capital through private placements.

PART II

OTHER INFORMATION

Item 1.	Legal Proceedings.						None
Item 2.	Changes in Securities.

	In 1998, board of directors authorized a 1 for 1000 reverse stock split upon
approval by the stockholders.  The reverse split was affected in 1999.  The
financial statements for all periods have been restated to reflect the
reverse stock split.

	In 1998, the board of directors also authorized several issuances of stock
for services rendered to the Company.  A total of 25,280,000 post reverse
split shares that were to be issued upon the reverse stock split.  The shares
were issued in July 1999.

Item 3.	Defaults Upon Senior Securities.				None
Item 4.	Submission of Matters to a Vote of Security Holders.

	In 1998, board of directors authorized a 1 for 1000 reverse stock split
upon approval by the stockholders.  The reverse split was affected in 1999.
The financial statements for all periods have been restated to reflect the
reverse stock split.

Item 5.	Other Information.		             				None
Item 6.	Exhibits and Reports on Form 8-K.				None



SIGNATURES

	Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned authorized officer.


Dated November 30, 1999
                       				Life Medical Technologies, Inc.

					                       /s/ Robert Kropf




<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                               0
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                       0
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
                                0
                                          0
<COMMON>                                     1,863,534
<OTHER-SE>                                 (1,838,254)
<TOTAL-LIABILITY-AND-EQUITY>                         0
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                         0
<EPS-BASIC>                                          0
<EPS-DILUTED>                                        0


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission